Avenda’s Platform for Personalized Prostate Cancer Mapping Earns FDA Clearance

Avenda Health’s AI-powered prostate cancer management and mapping platform centered on personalization has recently received 510(k) clearance from the FDA.

The cloud-based platform, named iQuest, uses a patient’s own diagnostic data to define the extent of the disease and create a cancer probability map with optimal treatment margins. It is aimed at urologists for use after a patient has already gotten diagnosed to help them decide how to best treat the disease based on each specific patient’s tumor.

Once a patient receives an MRI and biopsy, their data is uploaded into iQuest. A physician then confirms the uploaded information, and the platform creates a 3D cancer estimation map that shows the patient’s extent of tumor within the prostate.

Co-founder and CEO of Avenda Health, Shyam Natarajan, further explains, “That map and 3D information is now actionable and can aid physicians in making treatment decisions. If they are planning a targeted therapy, they can also use iQuest to generate a virtual treatment plan. iQuest aids the urologist in determining the best course of action for the patient by showing them the likely extent of disease and margin for targeted therapy, which is not possible with the standard of care.”

The platform’s algorithms were trained on hundreds of thousands of diagnostic patient data points, including MRI data, pathology data and other clinical information.

“In order to minimize bias, algorithms are validated by using held-out datasets from wholly separate institutions from the training dataset,” Natarajan said.

Join the HealthXL Masterclass on the ‘DTx Access Negotiation and Contracting with Commercial Health Plans in the US’ on 15th December. Click here to Request to Join.